FindTrial
Sign In

A Clinical Study to Assess Hair Regrowth in Bald Areas and Hair Thickness Improvement Using Exodense Hair Serum

An Open-Label, Single-Arm, Interventional Clinical Study to Evaluate the Efficacy and Safety of Exodense Hair Serum for Hair Regrowth in Bald Areas and Improvement in Hair Thickness Over a Period of 30 Days - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109742
Enrollment
34
Registered
2026-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Exodense Hair Serum: Topical hair serum applied once or twice daily on affected scalp areas for 30 days Control Intervention1: Not Applicable: This is an open-label, single-arm interven
no comparator or control group is included

Sponsors

SKINOVATE LASER & COSMETIC SURGERY CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy male and female subjects aged 18 55 years Subjects with mild to moderate hair thinning or localized bald patches Visible scalp in target area Good general health Willingness to provide written informed consent

Exclusion criteria

Exclusion criteria: Severe alopecia (complete baldness) Active scalp conditions (infection, dermatitis, psoriasis) Known hypersensitivity to hair products Use of: Hair growth treatments (within 1 month) Systemic medication affecting hair growth Recent hair procedures (PRP, transplant) Pregnant or breastfeeding women Participation in another study within 30 days Any condition interfering with evaluation

Design outcomes

Primary

MeasureTime frame
To assess hair regrowth in bald/thinning areas and re-densificationTimepoint: Baseline, Day 15, and Day 30—

Secondary

MeasureTime frame
To evaluate increase in hair thickness To assess reduction in visible scalp area To evaluate subject satisfaction To assess safety & tolerability Timepoint: At baseline, Day 15 & Day 30—

Countries

India

Contacts

Public ContactDr Avinash Bajirao Jadhav

Punawale Multispecialty Hospital

dr.avinashjadhav2@gmail.com07378306651

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026